Lucence

We're pleased to see our collaboration with Mayo Clinic Laboratories helping to expand access to LiquidHALLMARK®. Liquid biopsy continues to play an increasingly important role in precision oncology by supporting molecular profiling for treatment selection, therapy monitoring, and the identification of emerging resistance mechanisms. Thank you to Mayo Clinic Laboratories for highlighting LiquidHALLMARK®.

Today, our CEO, Dr Min-Han Tan, joined healthcare leaders at IHH HEALTHCARE SINGAPORE's FutureHealth event to discuss how prevention, longevity, and precision health are reshaping the future of care. As part of the launch and panel discussions, we shared about AgeQ™, a new future health assessment tool that helps people better understand how their bodies are aging using routine blood biomarkers. (Learn more about AgeQ™here - https://lnkd.in/g2jZPH4a) Healthcare is quickly moving beyond treating diseases after diagnosis. The opportunity lies in helping people understand their health earlier, enabling more informed decisions that support healthier years ahead. Thank you to IHH HEALTHCARE SINGAPORE for bringing together leaders from across healthcare, technology, and innovation to explore what's next for the future of health.

When an MCED test says it screens for over a hundred cancer subtypes, what does that actually mean? Subtypes, anatomical sites, and cancer types are not the same thing. Counting them separately is not the same as validating separate screening categories. Performance also varies widely by stage. In one clinical validation study, sensitivity at stage I was 16.8%. At stage IV: 90.1%.[1] And a positive result is not a diagnosis. Follow-up imaging, specialist review, and in some cases biopsy are still needed. Three questions worth asking before and after any MCED test: 1. What proportion of cancer incidence and mortality does this test cover? 2. How does sensitivity vary by cancer type and stage? 3. What follow-up pathway follows a positive result? Read more: https://lnkd.in/gjNiRwzF [1] Klein EA, et al. Ann Oncol. 2021; 32(9): 1167–1177.

Age is the greatest risk factor for cancer. But what if the real story is biological aging? Many factors linked to cancer risk, including smoking, alcohol, UV exposure, air pollution, physical inactivity, and poor diet quality, may seem unrelated. Yet many converge on the same biological pathways: chronic inflammation, metabolic dysfunction, oxidative stress, and DNA damage. These processes are not only associated with cancer development. They are also key drivers of biological aging. In our latest article, we explore why longevity medicine sits upstream of cancer prevention, and how understanding the biology of aging may help inform a more proactive approach to health. Read more: https://lnkd.in/gafjYp2J

What can cell-free RNA reveal beyond DNA? At ASCO Breakthrough 2026 today, Dr Michelle Pek from Lucence will be presenting new research on plasma cfRNA profiling in advanced non-small cell lung cancer. This exploratory study investigates how ctDNA and ctRNA together may support more complete molecular profiling — linking genomic alterations with RNA expression signals related to tumor burden, EGFR-mutant disease progression, inflammation, immune biology, and immunotherapy response. By adding RNA expression profiling to ctDNA, we aim to better understand molecular features of treatment response, resistance, and the tumor microenvironment that may not be visible through DNA-based profiling alone. We look forward to sharing our findings and connecting with the oncology community at ASCO Breakthrough 2026. Poster: Characterizing plasma circulating tumor RNA landscape in advanced NSCLC: Preliminary insights into treatment resistance and tumor microenvironment Poster Session C: Breast Cancer, Developmental Therapeutics, Genetics/Genomics/Multiomics, Gynecologic Cancer, Head and Neck Cancer Read the full abstract here: https://lnkd.in/gKjpDNha

We are honored to welcome Dr. Guru Sonpavde, MD, Director of Phase I Clinical Research and Genitourinary Oncology and Endowed Chair of Bladder Cancer Research at Advent Health Cancer Institute, and Professor of Medicine at the University of Central Florida, Orlando, Florida to the Lucence Medical Advisory Board. A recognized leader in genitourinary oncology, Dr. Sonpavde brings extensive expertise in translational research, therapeutic innovation, and patient-focused cancer care. His guidance will help shape Lucence’s continued efforts to advance precision diagnostics and deliver clinically meaningful insights to physicians and patients around the world. We look forward to working together to drive the future of precision oncology. Visit our website: www.lucence.com

When Angelina Jolie learned she carried a BRCA1 mutation, the result did not tell her she had cancer. It told her she was at increased risk of developing cancer in the future. That distinction highlights an important difference between two increasingly common applications of next-generation sequencing (NGS): • Cancer risk testing asks: "Am I at increased risk?" • Cancer screening asks: "Is cancer present now?" While they answer different questions, both aim to create opportunities for earlier action. In our latest article, we explore how risk testing and cancer screening complement one another. Read the full article: https://lnkd.in/gYzqh-CS

Thank you Mayo Clinic Laboratories for spotlighting our collaboration. At Lucence, we're committed to expanding access to comprehensive liquid biopsy testing that can provide actionable insights from a simple blood draw. LiquidHALLMARK® combines ctDNA and ctRNA analysis to help support precision oncology care across multiple cancer types. We are honored to work alongside Mayo Clinic Laboratories in bringing advanced molecular testing to clinicians and patients.

An important step forward for CSF liquid biopsy in neuro-oncology. The CNS Cancer Guidelines now include consideration of cerebrospinal fluid (CSF) ctDNA testing for high-grade gliomas and glioblastomas when tissue sampling is not feasible, highlighting the growing recognition of CSF liquid biopsy as a valuable tool in neuro-oncology. We're pleased to share that LiquidHALLMARK® CSF is now available in the U.S., offering comprehensive genomic profiling from cerebrospinal fluid, including detection of H3 K27M mutations. LiquidHALLMARK® CSF is available through our collaboration with Mayo Clinic Laboratories. To order the test or learn more, please contact your Mayo Clinic Laboratories representative. For patients who cannot undergo neurosurgical biopsy, or when diagnosis and treatment depend on molecular biomarkers, CSF liquid biopsy may help provide actionable molecular insights from a minimally invasive sample. Learn more: https://lnkd.in/gcP7hEMe